2nd Edition MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases (Time zone- Greenwich Mean Time (GMT)

3rd-4th December 2020
Sponsors
Gold

Volv

Volv

Volv was founded to allow customers to exploit latest developments in technology and data science to generate unique and powerful insights from data. Our mission is to speed science, reduce the cost of healthcare, and so enhance the economic output and well-being for all.

Using the flagship product, inTrigue, Volv finds undiagnosed and misdiagnosed rare disease patients from electronic healthcare records up to eight years earlier than traditional approaches.

 

Silver

Within3

Within3

Within3 invented a better way for life sciences companies to have conversations with the people who matter most—from doctors to patients to payers, and more. Our virtual engagement platform gives stakeholders the freedom to communicate anytime, anywhere, on any device. With tools for meaningful discussions and a dedicated client success team on every project, most Within3 projects achieve 100% stakeholder participation. To learn more and request a demo, visit www.within3.com.

Visiting Partners

Angelini

Angelini

Angelini Fine Chemicals is one of the major Italian CDMOs serving branded pharmaceutical industries. Equipped with state-of-the-art R&D labs and over 70.000 m2 cGMP manufacturing facility based in Aprilia (Southern Rome Area), Angelini Fine Chemicals is at the front-end of development and manufacturing of Adv. IMs., APIs and HPAPIs over 50 years, supporting custom chemical development and manufacturing programs - from early clinical lots up to commercial manufacturing, from 1-1000+kg up to multi-tons scale.

Speaking Partner

Mendelian

Mendelian

Mendelian is dedicated to helping doctors find undiagnosed patients early. Mendelian is a London-based digital health company committed to ending the diagnostic odyssey.  MendelScan is our expert-guided platform for disease discovery. We encode case finding criteria for hard-to-diagnose diseases, apply them to medical records, and enable our partners in the NHS to give patients the care they need.   We also partner across the rare disease space to accelerate the development of diagnostics and therapies.